Olivia Le Saux1, Claire Falandry2,3. 1. Medical Oncology Department, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. Olivia.le-saux@chu-lyon.fr. 2. Geriatric Oncology Department, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 3. CarMen biomedical research laboratory (Cardiovascular diseases, Metabolism, diabetology and Nutrition) INSERM UMR 1060, Université de Lyon, Oullins, France.
Abstract
PURPOSE OF THE REVIEW: In clinical practice, older patients are often undertreated due to underrepresentation in clinical trials and fear of toxicity. Our objective was therefore to review toxicities that are specific to older cancer patients, to review risk factors in order to help physicians guide their decisions, and to review interventions that can be implemented in routine clinical practice to prevent toxicity induced by cancer therapies. RECENT FINDINGS: On the whole, reviews report similar number and frequency as well as similar grade 3 or 4 adverse events between subjects older and younger than 65 years. Yet patients included in clinical trials are often not representative of real-life patients and are often fit older cancer patients. Moreover, tolerance to the additive impact of multiple adverse effects is different between older and younger patients. And specific symptoms such as stomatitis may cause a series of consequences such as dehydration, denutrition, renal insufficiency, and adverse events of renally excreted drugs. Older patients are at high risk of toxicity due to many factors but mainly due to the prevalence of frailty in this population that has been estimated to be around 40% increasing the risk of chemotherapy intolerance. As a consequence, interventions must be implemented according to altered domains of comprehensive geriatric assessment in order to improve anticancer tolerance. These interventions are reviewed here.
PURPOSE OF THE REVIEW: In clinical practice, older patients are often undertreated due to underrepresentation in clinical trials and fear of toxicity. Our objective was therefore to review toxicities that are specific to older cancerpatients, to review risk factors in order to help physicians guide their decisions, and to review interventions that can be implemented in routine clinical practice to prevent toxicity induced by cancer therapies. RECENT FINDINGS: On the whole, reviews report similar number and frequency as well as similar grade 3 or 4 adverse events between subjects older and younger than 65 years. Yet patients included in clinical trials are often not representative of real-life patients and are often fit older cancerpatients. Moreover, tolerance to the additive impact of multiple adverse effects is different between older and younger patients. And specific symptoms such as stomatitis may cause a series of consequences such as dehydration, denutrition, renal insufficiency, and adverse events of renally excreted drugs. Older patients are at high risk of toxicity due to many factors but mainly due to the prevalence of frailty in this population that has been estimated to be around 40% increasing the risk of chemotherapy intolerance. As a consequence, interventions must be implemented according to altered domains of comprehensive geriatric assessment in order to improve anticancer tolerance. These interventions are reviewed here.
Authors: G Candore; M P Grimaldi; F Listi; V Ferlazzo; G Colonna-Romano; M Motta; M Malaguarnera; G Fradá; D Lio; C Caruso Journal: Arch Gerontol Geriatr Suppl Date: 2002
Authors: Jeremy Walston; Evan C Hadley; Luigi Ferrucci; Jack M Guralnik; Anne B Newman; Stephanie A Studenski; William B Ershler; Tamara Harris; Linda P Fried Journal: J Am Geriatr Soc Date: 2006-06 Impact factor: 5.562
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Joseph D Tariman; Donna L Berry; Barbara Cochrane; Ardith Doorenbos; Karen G Schepp Journal: Oncol Nurs Forum Date: 2012-01 Impact factor: 2.172
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: James Cassidy; Leonard B Saltz; Bruce J Giantonio; Fairooz F Kabbinavar; Herbert I Hurwitz; Ulrich-Peter Rohr Journal: J Cancer Res Clin Oncol Date: 2009-11-11 Impact factor: 4.553
Authors: Laurie E Steffen McLouth; Fengmin Zhao; Taofeek K Owonikoko; Josephine L Feliciano; Nisha A Mohindra; Suzanne E Dahlberg; James L Wade; Gordan Srkalovic; Bradley W Lash; Joseph W Leach; Ticiana A Leal; Charu Aggarwal; David Cella; Suresh S Ramalingam; Lynne I Wagner Journal: Cancer Med Date: 2020-08-28 Impact factor: 4.452
Authors: Nina Rosa Neuendorff; Kah Poh Loh; Alice S Mims; Konstantinos Christofyllakis; Wee-Kheng Soo; Bediha Bölükbasi; Carlos Oñoro-Algar; William G Hundley; Heidi D Klepin Journal: Blood Adv Date: 2020-02-25